Drug intelligence / Profile preview

clonidine + trimeprazine

Development stage: Preclinical
Lead developer: Tris Pharma
Modality: Small Molecules
Administration: Oral

Overview

Clonidine is a centrally acting alpha-2 adrenergic agonist used primarily for hypertension, ADHD, and off-label for pruritus. Trimeprazine is an antihistamine with sedative properties, used mainly as an antipruritic and sedative. The combination of clonidine and trimeprazine has been reported in case studies to provide dramatic improvement in refractory pruritus associated with atopic dermatitis[1][6]. Both drugs can have additive effects on lowering blood pressure, potentially causing dizziness or fainting[6]. This combination is not a standard or widely marketed product but may be used off-label under medical supervision.

Other names: clonidine and trimeprazineCatapres and trimeprazine

Targets

HRH1 (Histamine H1 Receptor)ADRA1A (α1A)I1R (Nischarin)ADRA2A (α2A)

Beyond the preview

Go deeper on clonidine + trimeprazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clonidine + trimeprazine.

Explore the full profile